Jabil, a leader in engineering, manufacturing, and supply chain solutions, announced the acquisition of Pharmaceutics International (Pii), a contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.
Jabil is a leader in parenteral drug delivery, supporting markets like GLP-1s. This deal will significantly enhance Jabil’s existing Pharmaceutical Solutions offering, including developing and commercializing auto-injectors, pen injectors, inhalers, and on-body pumps. With the addition of Pii’s leading scientific insights, depth of product knowledge, and capabilities across aseptic filling, lyophilization, and oral solid dose manufacturing, Jabil can meet the clinical and commercial drug manufacturing demands of healthcare customers.
Launched in 1994, Pii’s footprint has grown to over 360,000 square feet across four sites on a single campus in Hunt Valley, Maryland. Pii’s state-of-the-art Good Manufacturing Practice (GMP) facilities contain over 70 manufacturing rooms, such as containment suites for handling high potency compounds and hormones, dedicated manufacturing suites for oral products (e.g., soft gels), an aseptic facility for injectables (e.g., vials, syringes, and cartridges), a formulation development center, and analytical and microbiology laboratories. This expertise will add a comprehensive portfolio of pharmaceutical development and manufacturing services to Jabil’s current healthcare solutions.
By joining Jabil, Pii gains access to an expanded global infrastructure, automation, and enhanced supply chain efficiencies, enabling even greater responsiveness and innovation for their pharmaceutical partners.
KEY QUOTES:
“As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain.”
- Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil
“Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers. The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil’s customer offering and support business growth potential as we enter the CDMO market.”
- James O’Gorman, Vice President, Pharmaceutical Solutions, at Jabil
“This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve.”
- John Fowler, President and CEO at Pii
“On behalf of our board and fellow shareholders at Athyrium Capital Management, Hildred Capital and Pharmascience Inc., I want to thank our management and staff for their splendid work in building the Company over the past several years. Jabil is the perfect owner to continue the momentum of the business. With their resources and capabilities, we believe our customers and employees will be well served going forward.”
- James Gale, Chairman of Pii and managing director of Signet Healthcare Partners
